WHO announces first Ebola vaccine clinical trial in DRC
The Tumaini trial will test the safety and efficacy of multiple vaccines, including mRNA and adenoviral vector candidates, against the Bundibugyo species.
The World Health Organization has announced the beginning of the first clinical trial of an Ebola vaccine in the outbreak in the Democratic Republic of Congo. Participants in the trial were vaccinated with the Ervebo vaccine in Bunia, the capital of the northeastern Ituri province, which is the epicentre of the outbreak.
Ervebo is approved for use against the Zaire strain of Ebola, but this full-scale human trial will see if it offers cross-protection against the Bundibugyo species behind the epidemic. WHO director-general Tedros Adhanom Ghebreyesus said on X that the trial will help understand whether vaccine candidates designed for the Bundibugyo virus work.
The Tumaini trial is a single trial framework that will test the safety, efficacy, and immunogenicity of multiple vaccines. It will use a ring vaccination approach to immunise contacts deemed to be at high risk of infection. The trial will include pregnant women and children aged 12 years and older to generate evidence for populations often excluded from clinical trials.
Two Bundibugyo-specific candidate vaccines are expected to enter the trial shortly. One is a ChAdOx1 adenoviral vector jab being developed by the University of Oxford, and the other is an mRNA vaccine from the US-based Moderna group. Both have received funding from the Coalition for Epidemic Preparedness Innovations.
The DRC declared its 17th and worst-ever Ebola outbreak in May, reporting more than 9,700 cases and over 4,600 deaths. The outbreak has been reported in four countries across eastern, central, and western Africa, giving it the widest geographic spread of any Ebola outbreak on the continent to date. In response, the WHO triggered a public health emergency of international concern.
Key facts
- The Tumaini trial will test the safety, efficacy, and immunogenicity of multiple vaccines.
- The DRC has reported more than 9,700 Ebola cases and over 4,600 deaths since declaring its 17th outbreak in May.
- Candidate vaccines include an mRNA vaccine from Moderna and a ChAdOx1 adenoviral vector jab from the University of Oxford.
Three perspectives
Neutral
The WHO is supporting a DRC-led effort to test various vaccine candidates against the Bundibugyo species of Ebola.
Positive
The trial will include pregnant women and children aged 12 years and older to generate evidence for populations often excluded from clinical trials.
Negative
The current Ebola outbreak has spread to four countries and has resulted in more than 4,600 deaths.
Your week in news, every Wednesday
The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.